The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Cyclosporin derivatives. Buy the report here.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Cyclosporin derivatives is a notable innovation area in the pharmaceutical industry

Cyclosporin is a cyclic peptide composed of 11 amino acids and inhibits calcineurin. Cyclosporins are a family of neutral, highly lipophilic, and cyclic undecapeptides containing unusual amino acids. Cyclosporin is approved for a variety of indications. The drug is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. Cyclosporin can also treat patients with severe active rheumatoid arthritis (RA) who do not respond to methotrexate alone.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 380+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cyclosporin derivatives.

Key players in cyclosporin derivatives – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to cyclosporin derivatives

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Immatics 1297 Unlock Company Profile
Philip Morris International 406 Unlock Company Profile
F. Hoffmann-La Roche 358 Unlock Company Profile
Bristol-Myers Squibb 315 Unlock Company Profile
Takeda Pharmaceutical 234 Unlock Company Profile
Protagonist Therapeutics 228 Unlock Company Profile
OncoTherapy Science 225 Unlock Company Profile
Amgen 164 Unlock Company Profile
Apellis Pharmaceuticals 159 Unlock Company Profile
Seagen 152 Unlock Company Profile
Bicycle Therapeutics 150 Unlock Company Profile
Centre National de la Recherche Scientifique 148 Unlock Company Profile
Merck & Co 134 Unlock Company Profile
Ironwood Pharmaceuticals 125 Unlock Company Profile
Ipsen 118 Unlock Company Profile
Caregen 112 Unlock Company Profile
Novo Nordisk Foundation 111 Unlock Company Profile
Ferring Holding 109 Unlock Company Profile
Aileron Therapeutics 105 Unlock Company Profile
GemVax & KAEL 104 Unlock Company Profile
UCB 99 Unlock Company Profile
Johnson & Johnson 97 Unlock Company Profile
Shanghai Techwell Biopharmaceutical 94 Unlock Company Profile
Forschungszentrum Julich 92 Unlock Company Profile
E. Merck 92 Unlock Company Profile
Sanofi 90 Unlock Company Profile
Palatin Technologies 84 Unlock Company Profile
Ministry of Trade and Industry, Singapore 83 Unlock Company Profile
Apitope International 80 Unlock Company Profile
Ambrx Biopharma 75 Unlock Company Profile
Vertex Pharmaceuticals 74 Unlock Company Profile
Equillium 70 Unlock Company Profile
MorphoSys 70 Unlock Company Profile
Novabiotics 70 Unlock Company Profile
Autoimmune Technologies 69 Unlock Company Profile
Pharma Mar 68 Unlock Company Profile
Administrators of Tulane Educational Fund 62 Unlock Company Profile
3-D Matrix 58 Unlock Company Profile
AbbVie 58 Unlock Company Profile
Baxter International 57 Unlock Company Profile
Niox Group 57 Unlock Company Profile
United Nations Industrial Development Organization 56 Unlock Company Profile
Ecole Polytechnique Federale de Lausanne 55 Unlock Company Profile
AFFiRiS 54 Unlock Company Profile
Dr. Reddy's Laboratories 52 Unlock Company Profile
Zealand Pharma 51 Unlock Company Profile
Biocon 51 Unlock Company Profile
Xigen Inflammation 50 Unlock Company Profile
Cellivery Therapeutics 47 Unlock Company Profile
Pharis Biotec 47 Unlock Company Profile

Source: GlobalData Patent Analytics

Immatics is the leading patent filer in cyclosporin derivatives. Immatics is a biopharmaceutical company focused on the development of T-cell immunotherapies to fight against cancer. Immatics is headquartered in Tuebingen, Germany. F. Hoffmann-La Roche and Bristol-Myers Squibb are the other key patent filers in cyclosporin derivatives.

In terms of application diversity, Western Sydney Local Health District (Australia) is the top company, followed by Warren Pharmaceuticals and Ipsen. By means of geographic reach, Ambrx Biopharma holds the top position. Adamed Pharma and BioMarin Pharmaceutical stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.